X

Trial Profile

An extension study assessing LUM-201

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibutamoren (Primary)
Indications Somatotropin deficiency
Focus Pharmacodynamics; Pharmacokinetics
Acronyms OraGrowtH211
Sponsors Lumos Pharma

Most Recent Events

10 May 2022 According to an Lumos Pharma media release, the company plan to conduct a interim analyses of data of trial by the end of 2022.
10 May 2022 According to an Lumos Pharma media release, based on a review of preliminary safety and efficacy data from both OraGrowtH trials in progress the FDA has lifted the partial hold and will now permit treatment with LUM-201 beyond twelve months. The company plans to extend the duration of the OraGrowtH212 Trial.
10 May 2022 Status changed from suspended to recruiting, according to an Lumos Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com